Correlation Between Universal Vision and Easywell Biomedicals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Universal Vision and Easywell Biomedicals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Universal Vision and Easywell Biomedicals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Universal Vision Biotechnology and Easywell Biomedicals, you can compare the effects of market volatilities on Universal Vision and Easywell Biomedicals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Universal Vision with a short position of Easywell Biomedicals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Universal Vision and Easywell Biomedicals.

Diversification Opportunities for Universal Vision and Easywell Biomedicals

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Universal and Easywell is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Universal Vision Biotechnology and Easywell Biomedicals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Easywell Biomedicals and Universal Vision is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Universal Vision Biotechnology are associated (or correlated) with Easywell Biomedicals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Easywell Biomedicals has no effect on the direction of Universal Vision i.e., Universal Vision and Easywell Biomedicals go up and down completely randomly.

Pair Corralation between Universal Vision and Easywell Biomedicals

Assuming the 90 days trading horizon Universal Vision Biotechnology is expected to generate 0.42 times more return on investment than Easywell Biomedicals. However, Universal Vision Biotechnology is 2.4 times less risky than Easywell Biomedicals. It trades about -0.03 of its potential returns per unit of risk. Easywell Biomedicals is currently generating about -0.35 per unit of risk. If you would invest  22,950  in Universal Vision Biotechnology on September 2, 2024 and sell it today you would lose (1,200) from holding Universal Vision Biotechnology or give up 5.23% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Universal Vision Biotechnology  vs.  Easywell Biomedicals

 Performance 
       Timeline  
Universal Vision Bio 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Universal Vision Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Universal Vision is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Easywell Biomedicals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Easywell Biomedicals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Universal Vision and Easywell Biomedicals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Universal Vision and Easywell Biomedicals

The main advantage of trading using opposite Universal Vision and Easywell Biomedicals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Universal Vision position performs unexpectedly, Easywell Biomedicals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Easywell Biomedicals will offset losses from the drop in Easywell Biomedicals' long position.
The idea behind Universal Vision Biotechnology and Easywell Biomedicals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets